Featured Research

from universities, journals, and other organizations

Long term prognosis for life birth after recurrent miscarriage

Date:
July 5, 2011
Source:
European Society of Human Reproduction and Embryology
Summary:
The first long-term follow-up study to look at the chances of having a live birth after recurrent miscarriage -- defined as at least three consecutive pregnancy losses -- found that approximately two-thirds of women with RM had at least one live birth after referral to specialist investigation.

The first long-term follow-up study to look at the chances of having a live birth after recurrent miscarriage -- defined as at least three consecutive pregnancy losses -- found that approximately two-thirds of women with RM had at least one live birth after referral to specialist investigation, a researcher told the annual conference of the ESHRE on July 5. Ms Marie Lund, said that her team's research would help give couples a more realistic prognosis of their chances of having a child after RM.

The researchers studied the records of 987 women with a minimum of three consecutive miscarriages, who had been referred to a specialist RM clinic between 1986 and 2008. Using data from the National Danish Birth Register they were able to see how many of the women had achieved a live birth after referral to the clinic. They also looked at the impact of maternal age at the time of referral, and the number of previous miscarriages as prognostic markers for future live births. The ages of the women at referral to the clinic ranged from 20 to 46 years.

"We found that, of all the women included in the study, 66.7% had achieved a subsequent live birth within five years after their first consultation in our clinic, and that this increased to 71.1% within 15 years after the first consultation," study leader, Professor Ole Christiansen, said. "The next step will be to compare the fecundity (ability to get pregnant resulting in live birth) of women with RM to that of an age-matched group of women from the general population with an equally strong wish to conceive since we are not, from the present study, able to conclude with regards to that."

"The women attending the clinic are encouraged to try to become pregnant, are closely monitored and receive appropriate treatment if relevant risk factors are present. However, in this study we did not specifically look at the effect of different treatments," said Ms Lund.

There are a number of possible reasons why some women attending the clinic did not have a live birth after referral, according to the researchers. One reason could be that they continue to miscarry in all subsequent pregnancies, but others could simply be due to increased age at each attempt, or damage to the Fallopian tubes caused by post-miscarriage pelvic inflammation. Additionally, the couple may eventually give up trying for a pregnancy due to fear of another miscarriage, or the pregnancy attempts are given up due to divorce.

Most studies of RM to date have looked at miscarriage rate in the next pregnancy as an outcome measure. "Because an essential part of the management of couples with RM is to be able to advice on the prognosis for future pregnancy outcome, we performed this study to investigate the outcome measure of live birth after a certain time period, since we believe this is more relevant from the patient's perspective and also more transparent than just looking at miscarriage rate in the next pregnancy. We hope that estimating the chances having a live-born child will give couples affected by RM a more realistic prognosis for future pregnancy success," Professor Christiansen concluded.


Story Source:

The above story is based on materials provided by European Society of Human Reproduction and Embryology. Note: Materials may be edited for content and length.


Cite This Page:

European Society of Human Reproduction and Embryology. "Long term prognosis for life birth after recurrent miscarriage." ScienceDaily. ScienceDaily, 5 July 2011. <www.sciencedaily.com/releases/2011/07/110705091506.htm>.
European Society of Human Reproduction and Embryology. (2011, July 5). Long term prognosis for life birth after recurrent miscarriage. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/07/110705091506.htm
European Society of Human Reproduction and Embryology. "Long term prognosis for life birth after recurrent miscarriage." ScienceDaily. www.sciencedaily.com/releases/2011/07/110705091506.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins